Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/absci-corp">Absci </a>is a high-growth, high-risk synthetic biology company leveraging a proprietary AI-powered platform to accelerate the discovery and development of biologic drugs, primarily antibodies.</li>
  <li>The company's business model is dual-pronged, focusing on revenue-generating partnerships with pharmaceutical companies and developing its own internal pipeline of drug candidates, such as ABS-101 for IBD and ABS-201 for hair loss.</li>
  <li>Financially, <a href="https://smartkarma.com/entities/absci-corp">Absci </a>is in a pre-profitability stage, characterized by significant R&amp;D investment, negative net income and cash flow, and a reliance on capital markets and collaboration revenue to fund operations.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Absci is a high-growth, high-risk synthetic biology company leveraging a proprietary AI-powered platform to accelerate the discovery and development of biologic drugs, primarily antibodies.
  The company's business model is dual-pronged, focusing on revenue-generating partnerships with pharmaceutical companies and developing its own internal pipeline of drug candidates, such as ABS-101 for IBD and ABS-201 for hair loss.
  Financially, Absci is in a pre-profitability stage, characterized by significant R&amp;D investment, negative net income and cash flow, and a reliance on capital markets and collaboration revenue to fund operations.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

United States

AbSci Corporation operates as a synthetic biology company. The Company translates and unifies biologic drug discovery and development processes with its integrated drug creation platform. AbSci serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Absci (ABSI US)

Primer: Absci (ABSI US) - Aug 2026

Absci is a high-growth, high-risk synthetic biology company leveraging a proprietary AI-powered platform to accelerate the discovery and...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)